The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Open accessAbstract
BACKGROUND: Mutations in RPE65 cause Leber's congenital amaurosis, a progressive retinal degenerative disease that severely impairs sight in children. Gene therapy can result in modest improvements in night vision, but knowledge of its efficacy in humans is limited. METHODS: We performed a phase 1-2 open-label trial involving 12 participants to evaluate the safety and efficacy of gene therapy with a recombinant adeno-associated virus 2/2 (rAAV2/2) vector carrying the RPE65 complementary DNA, and measured visual function over the course of 3 years. Four participants were administered a lower dose of the vector, and 8 were administered a higher dose. In a parallel study in dogs, we investigated the relationship among vector dose, visual function, and electroretinography (ERG) findings. RESULTS: Improvements in retinal sensitivity were evident, to varying extents, in six participants for up to 3 years, peaking at 6 to 12 months after treatment and then declining. No associated improvement in retinal function was detected by means of ERG. Three participants had intraocular inflammation, and two had clinically significant deterioration of visual acuity. The reduction in central retinal thickness varied among participants. In dogs, RPE65 gene therapy with the same vector at lower doses improved vision-guided behavior, but only higher doses resulted in improvements in retinal function that were detectable with the use of ERG. CONCLUSIONS: Gene therapy with rAAV2/2 RPE65 vector improved retinal sensitivity, albeit modestly and temporarily. Comparison with the results obtained in the dog model indicates that there is a species difference in the amount of RPE65 required to drive the visual cycle and that the demand for RPE65 in affected persons was not met to the extent required for a durable, robust effect. (Funded by the National Institute for Health Research and others; ClinicalTrials.gov number, NCT00643747.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ocular AAV therapies leading to a permanent reduction in visual acuity following intraocular inflammation (9–11)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV dose-dependent intraocular inflammation and a few instances of persistent loss of visual acuity have been independently reported in clinical trials following subretinal AAV administration despite prophylactic immunosuppression (9–11).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the phase 1/2 dose-escalation trials for RPE65-associated LCA, choroideremia, and retinitis pigmentosa GTPase regulator (RPGR)-associated X-linked retinitis pigmentosa, patients receiving higher doses of AAV have presented with various signs of retinal inflammation, including vitritis, retinitis, and choroiditis,2,6,7 implicating the presence of a cell-mediated immune response.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the perceived low immunogenicity of AAV and relative immune privilege of the intraocular environment,8 dose-dependent retinal inflammation, or gene therapy-associated uveitis (GTAU), has been observed in many retinal gene therapy trials, which limits the vector dose and therapeutic efficacy.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [45]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is clinically important as intraocular inflammation could lead to irreversible loss of retinal cells, deterioration of visual function and reduced durability of treatment effect associated with a costly one-off treatment.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, one participant developed anterior uveitis at 2 weeks, followed by CRA and reduced visual acuity by 6 months.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two participants developed optic disc swelling, retinal vascular tortuosity/sheathing and mild vitritis.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three out of eight participants who received the higher dose of vector (1 × 10 12 vg/eye) but none in the lower dose cohort (1 × 10 11 vg/eye) developed intraocular inflammation despite prophylactic peri-operative immunosuppression.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, GTAU is often diagnosed shortly after the withdrawal of systemic immunosuppression prophy laxis (Dimopoulos et al., 2018) or when the dose reaches around 15 -20 mg for slower tapers, and sometimes several weeks to months after vector administration (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In phase I/II clinical trials for RPE65-LCA at University College London (ClinicalTrials.gov: NCT00643747), ocular inflammation was noted following SRI of 1 × 1012 vg of AAV2-RPE65.71,99”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [99]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although adeno-associated viral (AAV) vector-mediated retinal gene therapies have demonstrated efficacy”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The intraocular inflammation is dose-dependent and can sometimes last for months or even years following treatment, leading to irreversible retinal structural damage and reduced visual function if uncontrolled (Bainbridge et al., 2015).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2015
Experimental — accuracy not yet measuredIn the citing paper
“subfoveal viral gene therapy has been associated with various adverse effects, such as RPE alterations, retinal thinning, foveal morphological changes, vision loss, and the variable duration of clinical effects [281,294,296,297,298].”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [296]
In the citing paper
“Dose-dependent immune responses have also been observed, with high doses potentially leading to persistent inflammation and clinically significant vision loss in patients receiving high-dose AAV2 vector-based subretinal RPE65 therapy [296].”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [296]
In the citing paper
“However, some adverse events linked to the glucocorticoids themselves have already been described in retinal rAAV trials which point out the need for other alternatives to mitigate the inflammation [37].”
From Risk mitigation of immunogenicity: a key to personalized retinal gene therapy (2021) · cites this paper as [37]
In the citing paper
“The results showed that retinal sensitivity was improved; however, the final transgene expression in the participants from the high dose group was adversely affected by ocular inflammation or immune responses [48].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [48]
In the citing paper
“Nonetheless, inflammatory reactions to gene therapy in the eye have led to permanent vision loss for some patients7–9.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Self-citationStatistics Notes: Measurement error
Bland, J. M., & Altman, D. G. (1996) · BMJ · doi:10.1136/bmj.313.7059.744 · Cited by 1,084
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Leber congenital amaurosis: Genes, proteins and disease mechanisms
den Hollander, A. I., Roepman, R., Koenekoop, R. K., & Cremers, F. P. M. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.003 · Cited by 811
Cideciyan, A. V., Alemán, T. S., Boye, S. L., Schwartz, S., Kaushal, S., Román, A. J., Pang, J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 674
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Research works printed but not linked: 3
- Poehner WJ, 2000, Mol Vis, 6, 192
- Geller SF, 2001, Invest Ophthalmol Vis Sci, 42, 1363
- 10.1056/NEJMoa1412965 · DOI
Cited by
Sorted by citations
Items 301–400 of 743
Alemán, T. S., Miller, A. J., Maguire, K. H., Aleman, E. M., Serrano, L. W., O’Connor, K., Bedoukian, E. C., Leroy, B. P., Maguire, A. M., & Bennett, J. (2021) · Clinical ophthalmology · doi:10.2147/opth.s292527 · Cited by 26
The Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease
Velazquez, L. A. M., & Ballios, B. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111542 · Cited by 27
A clinically viable approach to restoring visual function using optogenetic gene therapy
Yan, B., Viswanáthan, S., Brodie, S. E., Deng, W., Coleman, K. E., Hauswirth, W. W., & Nirenberg, S. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.05.005 · Cited by 28
Biomechanical considerations for optimising subretinal injections
L’Abbate, D., Prescott, K., Geraghty, B., Kearns, V., & STEEL, D. H. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.05.004 · Cited by 26
Targeting vascular endothelial growth factor using retinal gene therapy
Chung, S. H., Frick, S. L., & Yiu, G. C. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4417 · Cited by 26
Zhu, L., Nie, L., Xie, S., Li, M., Zhu, C., Qiu, X., Kuang, J., Liu, C., Lu, C., Li, W., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108600 · Cited by 27
Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions
Banou, L., Sarrafpour, S., Teng, C. C., & Liu, J. (2024) · The Yale Journal of Biology and Medicine · doi:10.59249/hwid7537 · Cited by 26
Accurate Quantification of AAV Vector Genomes by Quantitative PCR
de la Cámara, C. M.-F., McClements, M. E., & MacLaren, R. E. (2021) · Genes · doi:10.3390/genes12040601 · Cited by 26
CNGB1 ‐related rod‐cone dystrophy: A mutation review and update
Nassisi, M., Smirnov, V. M., Hernandez, C. S., Mohand‐Saïd, S., Condroyer, C., Antonio, A., Kuehlewein, L., Kempf, M., Kohl, S., Wissinger, B., et al. (2021) · Human Mutation · doi:10.1002/humu.24205 · Cited by 24
Self-citationRecent Developments in Gene Therapy for Neovascular Age-Related Macular Degeneration: A Review
Finocchio, L., Zeppieri, M., Gabai, A., Toneatto, G., Spadea, L., & Salati, C. (2023) · Biomedicines · doi:10.3390/biomedicines11123221 · Cited by 31
Ellsworth, J. L., Gingras, J., Smith, L. J., Rubin, H. L., Seabrook, T. A., Patel, K., Zapata, N., Olivieri, K. C., O’Callaghan, M., Chlipala, E. A., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225582 · Cited by 25
A review of electroretinography waveforms and models and their application in the dog
Pasmanter, N., & Petersen‐Jones, S. M. (2020) · Veterinary Ophthalmology · doi:10.1111/vop.12759 · Cited by 25
Self-citationPetit, L., Ma, S., Cheng, S.-Y., Gao, G., & Punzo, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.020 · Cited by 24
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“Consequently, GTAU is often diagnosed shortly after the withdrawal of systemic immunosuppression prophylaxis (Dimopoulos et al., 2018) or when the dose reaches around 15 – 20 mg for slower tapers, and sometimes several weeks to months after vector administration (Bainbridge et al., 2015).”
InfluentialUtility of Self-Destructing CRISPR/Cas Constructs for Targeted Gene Editing in the Retina
Fan, L., Hung, S. S. C., Khalid, M. K. N. M., Wang, J.-H., Chrysostomou, V., Wong, V. H. Y., Singh, V., Wing, K., Tu, L., Bender, J. A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.021 · Cited by 24
Farmer, C., Bullement, A., Packman, D., Long, L., Robinson, S., Nikram, E., Hatswell, A. J., Meléndez‐Torres, G. J., & Crathorne, L. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00953-z · Cited by 24
Gene therapy strategies for rare monogenic disorders with nuclear or mitochondrial gene mutations
Wang, Y., Hu, L., Zhou, T., Qi, L., Xing, L., Lee, J., Wang, F., Oh, Y., & Jiang, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121108 · Cited by 25
Wang, Y.-C., Wu, Y., Choi, J. Y., Allington, G., Zhao, S., Khanfar, M., Yang, K., Fu, P.-Y., Wrubel, M., Yu, X., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020175 · Cited by 23
Robust cone-mediated signaling persists late into rod photoreceptor degeneration
Scalabrino, M. L., Thapa, M., Chew, L. A., Zhang, E., Xu, J., Sampath, A. P., Chen, J., & Field, G. D. (2022) · eLife · doi:10.7554/elife.80271 · Cited by 27
Prostaglandin-based rAAV-mediated glaucoma gene therapy in Brown Norway rats
Chern, K. J., Nettesheim, E. R., Reid, C. A., Li, N. W., Marcoe, G. J., & Lipinski, D. M. (2022) · Communications Biology · doi:10.1038/s42003-022-04134-w · Cited by 24
Li, S., Samardzija, M., Yang, Z., Grimm, C., & Jin, M. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3857-15.2016 · Cited by 26
Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase
Cagin, U., Puzzo, F., Gómez, M. J., Moya‐Nilges, M., Sellier, P., Abad, C., van Wittenberghe, L., Danièle, N., Guerchet, N., Gjata, B., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.025 · Cited by 25
Leber Congenital Amaurosis / Early-Onset Severe Retinal Dystrophy Overview
Kumaran, N., Pennesi, M. E., Yang, P. G., Trzupek, K. M., Schlechter, C. L., Moore, A. T., Weleber, R. G., & Michaelides, M. (2018) · Europe PMC (PubMed Central) · Cited by 24
Self-citationMatet, A., Kostic, C., Bemelmans, A.-P., Moulin, A., Rosolen, S. G., Martin, S., Mavilio, F., Amirjanians, V., Stieger, K., Lorenz, B., et al. (2017) · Translational Research · doi:10.1016/j.trsl.2017.06.012 · Cited by 20
Vandamme, C., Xicluna, R., Hesnard, L., Devaux, M., Jaulin, N., Guilbaud, M., Le Duff, J., Couzinié, C., Moullier, P., Saulquin, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03110 · Cited by 23
PAX6 MiniPromoters drive restricted expression from rAAV in the adult mouse retina
Hickmott, J. W., Chen, C., Arenillas, D. J., Korecki, A. J., Lam, S. L., Molday, L. L., Bonaguro, R. J., Zhou, M., Chou, A., Mathelier, A., et al. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.51 · Cited by 23
Bougioukli, S., Saitta, B., Sugiyama, O., Tang, A., Elphingstone, J. W., Evseenko, D. A., & Lieberman, J. R. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.054 · Cited by 23
The Landscape of Non-Viral Gene Augmentation Strategies for Inherited Retinal Diseases
Toualbi, L., Toms, M., & Moosajee, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052318 · Cited by 22
So, W. Y., Liu, W. N., Teo, A. K. K., Rutter, G. A., & Han, W. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb1038 · Cited by 23
Animals Models of Inherited Retinal Disease
Moshiri, A. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000368 · Cited by 23
Monobac System–A Single Baculovirus for the Production of rAAV
Galibert, L., Jacob, A., Savy, A., Dickx, Y., Bonnin, D., Lecomte, C., Rivollet, L., Sanatine, P., Fontaine, M. B., Bec, C. L., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9091799 · Cited by 25
López, J., Borchert, M., Lee, T. C., & Nagiel, A. (2022) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-321488 · Cited by 23
Communicating the Promise for Ocular Gene Therapies: Challenges and Recommendations
Benjaminy, S., Kowal, S. P., MacDonald, I. M., & Bubela, T. M. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.05.026 · Cited by 24
Verhenne, S., Vandeputte, N., Pareyn, I., Izsvák, Z., Rottensteiner, H., Deckmyn, H., Meyer, S. F. D., & Vanhoorelbeke, K. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308680 · Cited by 23
Concepts and Strategies in Retinal Gene Therapy
Aguirre, G. D. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22978 · Cited by 24
Kavita, U., Dai, Y., Salvador, L., Miller, W., Adam, L. P., Lévesque, P., Zhang, Y. J., Ji, Q., & Pillutla, R. C. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.131 · Cited by 23
An optimized treatment protocol for subretinal injections limits intravitreal vector distribution
Reichel, F. F. L., Wozar, F., Seitz, I., Ochakovski, A., Bartz-Schmidt, K. U., Peters, T., & Fischer, M. D. (2021) · Ophthalmology Science · doi:10.1016/j.xops.2021.100050 · Cited by 22
Meng, X., Jia, R., Zhao, X., Zhang, F., Chen, S., Yu, S., Liu, X., Dou, H., Feng, X., Zhang, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48092-9 · Cited by 28
Shen, X., Xu, Y., Bai, Z., Ma, D., Niu, Q., Meng, J., Fan, S., Zhang, L., Hao, Z., Zhang, X., et al. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.148 · Cited by 23
AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice
Keng, C. T., Yogarajah, T., Lee, R. C. H., Muhammad, I. B. H., Chia, B. S., Vasandani, S. R., Lim, D. S., Guo, K., Wong, Y. H., Mok, C. K., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104682 · Cited by 27
Shin, J., Kim, H. S., Vargas, A., Yu, W., Eom, Y. S., Craft, C. M., & Lee, E.-J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167102 · Cited by 22
Maurya, S., & Jayandharan, G. R. (2020) · Virus Research · doi:10.1016/j.virusres.2020.197966 · Cited by 22
Retinal Remodeling: Concerns, Emerging Remedies and Future Prospects
Krishnamoorthy, V., Cherukuri, P., Poria, D., Goel, M., Dagar, S., & Dhingra, N. K. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00038 · Cited by 23
Carvalho, C., Lemos, L., Antas, P., & Seabra, M. C. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1270561 · Cited by 21
Cao, X., Yung, J., Mak, H., & Leung, C. K. S. (2019) · Gene Therapy · doi:10.1038/s41434-019-0060-0 · Cited by 20
Retina-directed gene therapy: Achievements and remaining challenges
Biber, J., Gandor, C. L. A., Bećirović, E., & Michalakis, S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108862 · Cited by 25
Copy number variations and multiallelic variants in Korean patients with Leber congenital amaurosis.
Surl, D., Shin, S., Lee, S., Choi, J. R., Lee, J., Byeon, S. H., Han, S., Lim, H. T., & Han, J. (2020) · PubMed Central · Cited by 21
Wolfram syndrome: new pathophysiological insights and therapeutic strategies
Mishra, R., Chen, B. S., Richa, P., & Yu‐Wai‐Man, P. (2021) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040211039518 · Cited by 25
Kajtna, J., Tsang, S. H., & Koch, S. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04161-0 · Cited by 21
Malvasi, M., Casillo, L., Avogaro, F., Abbouda, A., & Vingolo, E. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813756 · Cited by 21
Bunce, C., Zekite, A., Wormald, R., & Bowman, R. J. C. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016888 · Cited by 21
Srikrupa, N. N., Srilekha, S., Sen, P., Arokiasamy, T., Meenakshi, S., Bhende, M. P., Kapur, S., & Soumittra, N. (2017) · Clinical Genetics · doi:10.1111/cge.13159 · Cited by 21
Early onset flecked retinal dystrophy associated with new compound heterozygous RPE65 variants.
Katagiri, S., Hosono, K., Hayashi, T., Kurata, K., Mizobuchi, K., Matsuura, T., Yoshitake, K., Iwata, T., Nakano, T., & Hotta, Y. (2018) · Europe PMC (PubMed Central) · Cited by 21
3D cell-laden polymers to release bioactive products in the eye
Orive, G., Santos‐Vizcaíno, E., Pedraz, J. L., Hernández, R. M., Ramirez, J. E. V., Dolatshahi‐Pirouz, A., Khademhosseini, A., Peppas, N. A., & Emerich, D. F. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.10.002 · Cited by 21
MacDonald, I. M., Moen, C., Duncan, J. L., Tsang, S. H., Cehajic-Kapetanovic, J., & Aleman, T. S. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.3.17 · Cited by 20
CRISPR Technology for Ocular Angiogenesis
Chung, S. H., Sin, T.-N., Ngo, T., & Yiu, G. C. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.594984 · Cited by 21
Gamm, D. M., Wong, R., & Panelists, A. T. A. W. (2015) · Translational Vision Science & Technology · doi:10.1167/tvst.4.6.2 · Cited by 20
Early-Onset Progressive Degeneration of the Area Centralis in RPE65-Deficient Dogs
Mowat, F. M., Gervais, K. J., Occelli, L. M., Annear, M. J., Querubin, J. R., Bainbridge, J. W., Smith, A. J., Ali, R. R., & Petersen‐Jones, S. M. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-21930 · Cited by 21
Self-citationLeber’s Congenital Amaurosis and Gene Therapy
Takkar, B., Bansal, P., & Venkatesh, P. (2017) · The Indian Journal of Pediatrics · doi:10.1007/s12098-017-2394-1 · Cited by 19
Severe Loss of Tritan Color Discrimination in RPE65 Associated Leber Congenital Amaurosis
Kumaran, N., Ripamonti, C., Kalitzeos, A. A., Rubin, G. S., Bainbridge, J. W., & Michaelides, M. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22905 · Cited by 20
Self-citationWu, Z., Cimetta, R., Caruso, E., & Guymer, R. H. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.4.16 · Cited by 20
Generation of Nonhuman Primate Model of Cone Dysfunction through In Situ AAV-Mediated CNGB3 Ablation
Lin, Q., Lv, J., Wu, K., Zhang, C.-J., Liu, Q., & Jin, Z. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.08.007 · Cited by 19
Gene Therapy to the Retina and the Cochlea
Crane, R., Conley, S. M., Al‐Ubaidi, M. R., & Naash, M. I. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.652215 · Cited by 24
Leber’s congenital amaurosis and the role of gene therapy in congenital retinal disorders
Sharif, W., & Sharif, Z. (2017) · International Journal of Ophthalmology · doi:10.18240/ijo.2017.03.24 · Cited by 20
Split AAV8 Mediated ABCA4 Expression for Gene Therapy of Mouse Stargardt Disease (STGD1)
Li, R., Jing, Q., She, K., Wang, Q., Jin, X., Zhao, Q., Su, J., Song, L., Fu, J., Wu, X., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.017 · Cited by 21
Risk mitigation of immunogenicity: a key to personalized retinal gene therapy
Varin, J., Morival, C., Maillard, N., Adjali, O., & Cronin, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312818 · Cited by 19
Corydon, T. J., & Bek, T. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101323 · Cited by 20
den Hollander, A. I. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18167 · Cited by 19
Base and Prime Editing in the Retina—From Preclinical Research toward Human Clinical Trials
Yee, T., & Wert, K. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012375 · Cited by 21
Kvanta, A., Rangaswamy, N. V., Holopigian, K., Watters, C., Jennings, N., Liew, M., Bigelow, C. E., Grosskreutz, C. L., Burstedt, M. S. I., Venkataraman, A. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51575-4 · Cited by 19
Gene Therapy for Age-Related Macular Degeneration
Constable, I. J., Blumenkranz, M. S., Schwartz, S. D., Barone, S. B., Lai, C., & Rakoczy, E. P. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000222 · Cited by 19
Dai, X., He, Y., Zhang, H., Zhang, Y., Liu, Y., Wang, M., Chen, H., & Pang, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188032 · Cited by 20
Caring for Hereditary Childhood Retinal Blindness
Jauregui, R., Cho, G. Y., Takahashi, V. K. L., Takiuti, J. T., Bassuk, A. G., Mahajan, V. B., & Tsang, S. H. (2018) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.201851 · Cited by 19
Silica cloaking of adenovirus enhances gene delivery while reducing immunogenicity
Sapre, A. A., Yong, G., Yeh, Y.-S., Ruff, L. E., Plaut, J. S., Sayar, Z., Agarwal, A., Martinez, J., Nguyen, T. N., Liu, Y.-T., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.034 · Cited by 19
Hoshino, Y., Nishide, K., Nagoshi, N., Shibata, S., Moritoki, N., Kojima, K., Tsuji, O., Matsumoto, M., Kohyama, J., Nakamura, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46069-z · Cited by 20
Developing Cell-Based Therapies for RPE-Associated Degenerative Eye Diseases
M’Barek, K. B., Habeler, W., Régent, F., & Monville, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-28471-8_3 · Cited by 19
CRISPR genome engineering for retinal diseases
Kantor, A., McClements, M. E., Peddle, C. F., Fry, L. E., Salman, A., Cehajic‐Kapetanovic, J., Xue, K., & MacLaren, R. E. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.024 · Cited by 19
Genetics and age-related macular degeneration: a practical review for the clinician
Schwartz, S. G., Hampton, B. M., Kovach, J. L., & Brantley, M. A. (2016) · Clinical ophthalmology · doi:10.2147/opth.s109723 · Cited by 20
The pigmented epithelium, a bright partner against photoreceptor degeneration
Letelier, J., Bovolenta, P., & Martínez‐Morales, J. R. (2017) · Journal of Neurogenetics · doi:10.1080/01677063.2017.1395876 · Cited by 20
Immunology of Retinitis Pigmentosa and Gene Therapy–Associated UveitisPreprint
Yang, P. G., Mustafi, D., & Pepple, K. L. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041305 · Cited by 20
Vendomèle, J., Dehmani, S., Khebizi, Q., Galy, A., & Fisson, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00504 · Cited by 18
Jia, R., Meng, X., Chen, S., Zhang, F., Du, J., Liu, X., & Yang, L. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac181 · Cited by 19
Investor Outlook: Focus on Upcoming LCA2 Gene Therapy Phase III Results
Schimmer, J., & Breazzano, S. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.29001.sch · Cited by 18
Viral Vectors, Engineered Cells and the CRISPR Revolution
DiCarlo, J. E., Deeconda, A., & Tsang, S. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_1 · Cited by 19
Recent Advancements in Gene Therapy for Hereditary Retinal Dystrophies
Öner, A. (2017) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.41017 · Cited by 19
LONGITUDINAL STUDY OF RPE65-ASSOCIATED INHERITED RETINAL DEGENERATIONS
Pierrache, L. H. M., Ghafaryasl, B., Khan, M. I., Yzer, S., van Genderen, M. M., Schuil, J., Boonstra, F. N., Pott, J. W. R., de Faber, J. T., Tjon-Fo-Sang, M. J. H., et al. (2020) · Retina · doi:10.1097/iae.0000000000002681 · Cited by 19
Self-citationRobert, M.-A., Nassoury, N., Chahal, P. S., Venne, M.-H., Racine, T., Qiu, X., Kobinger, G., Kamen, A., Gilbert, R., & Gaillet, B. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.101 · Cited by 19
Song, H., Bush, R. A., Zeng, Y., Qian, H., Wu, Z., & Sieving, P. A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.006 · Cited by 17
Georgiou, M., Ali, N., Yang, E., Grewal, P. S., Rotsos, T., Pontikos, N., Robson, A. G., & Michaelides, M. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01759-8 · Cited by 18
Self-citationUse of gene therapy for optic nerve protection: Current concepts
Xu, K., Yu, L., Wang, Z., Lin, P., Zhang, N., Xing, Y., & Yang, N. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1158030 · Cited by 19
Novack, G. D., & Robin, A. L. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2451 · Cited by 17
Chan, S., Bubela, T. M., Dimopoulos, I. S., Freund, P. R., Varkouhi, A. K., & MacDonald, I. M. (2016) · Ophthalmic Genetics · doi:10.3109/13816810.2015.1088958 · Cited by 17
Content generation for patient-reported outcome measures for retinal degeneration therapeutic trials
Lacy, G. D., Abalem, M. F., Popova, L., Santos, E. P., Yu, G., Rakine, H. Y., Rosenthal, J. M., Ehrlich, J. R., Musch, D. C., & Jayasundera, T. (2020) · Ophthalmic Genetics · doi:10.1080/13816810.2020.1776337 · Cited by 17
Cortical processing of global form, motion and biological motion under low light levels
Burton, E., Wattam-Bell, J., Rubin, G. S., Atkinson, J., Braddick, O., & Marko Nardini, A. (2016) · Vision Research · doi:10.1016/j.visres.2016.01.008 · Cited by 17
Self-citationAdeno-associated virus (AAV) reduces cortical dendritic complexity in a TLR9-dependent mannerPreprint
Suriano, C. M., Verpeut, J. L., Kumar, N., Ma, J., Jung, C., & Boulanger, L. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.28.462148 · Cited by 17
Ross, M., Obolensky, A., Averbukh, E., Ezra-Elia, R., Yamin, E., Honig, H., Dvir, H., Rosov, A., Hauswirth, W. W., Gootwine, E., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.023 · Cited by 16
Seitz, I. P., Wozar, F., Ochakovski, G. A., Reichel, F. F., Gelisken, F., Bartz-Schmidt, K. U., Peters, T., & Fischer, M. D. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100516 · Cited by 16
Lüscher, C., Emiliani, V., Farahany, N. A., Gittis, A. H., Gradinaru, V., High, K. A., Roska, B., Sahel, J., Yizhar, O., Zeng, H., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02097-9 · Cited by 24
Restoring Vision Using Stem Cells and Transplantation
Cuevas, E., Parmar, P. A., & Sowden, J. C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-27378-1_92 · Cited by 19
RPE65-Related Leber Congenital Amaurosis / Early-Onset Severe Retinal Dystrophy
Chao, D. L., Burr, A., & Pennesi, M. E. (2019) · Europe PMC (PubMed Central) · Cited by 16
Metadata
- Authors
- Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., Feathers, K. L., Luong, V. A., Yzer, S., Balaggan, K., Viswanathan, A., de Ravel, T. J. L., Casteels, I., Holder, G. E., Tyler, N., Fitzke, F. W., Weleber, R. G., Nardini, M., Moore, A. T., Thompson, D. A., Petersen-Jones, S. M., Michaelides, M., van den Born, L. I., Stockman, A., Smith, A. J., Rubin, G., & Ali, R. R.
- Affiliations
- Moorfields Eye Hospital (GB)
- Michigan State University (US)
- University of Michigan (US)
- Rotterdam Eye Hospital (NL)
- Universitair Ziekenhuis Leuven (BE)
- Oregon Health & Science University (US)
- ORCID
- Bainbridge, James W.B.
- Sundaram, Venki
- Robbie, Scott J.
- Georgiadis, Anastasios
- Mowat, Freya M.
- Beattie, Stuart G.
- Yzer, Suzanne
- Balaggan, Kamaljit
- Viswanathan, Ananth
- Casteels, Ingele
- Holder, Graham E.
- Tyler, Nick
- Weleber, Richard G.
- Moore, Anthony T.
- Thompson, Debra A.
- Michaelides, Michel
- Smith, Alexander J.
- Rubin, Gary
- Ali, Robin R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1887-1897
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4497809
- OpenAlex
- W265142245
- Semantic Scholar
- 31832b3aa3500171fc5f2a951f0a4124bd40068d
- Cited by
- 743
- References
- 29
- Citations by year
- 2026: 36 · 2025: 36 · 2024: 46 · 2023: 44 · 2022: 63 · 2021: 92 · 2020: 81 · 2019: 68 · 2018: 79 · 2017: 97 · 2016: 72 · 2015: 27
- FWCI
- 39.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Durham Research Online (Durham University) (acceptedVersion)
- Durham Research Online (Durham University) (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Wellcome Trust
- Massachusetts Medical Society
- National Institute for Health and Care Research (NF-SI-0507-10204, NF-SI-0513-10074, NIHR-RP-011-003)
- Sir Jules Thorn Charitable Trust
- University College London
- European Commission
- Ulverscroft Foundation
- Durham University
- KU Leuven
- Moorfields Eye Hospital NHS Foundation Trust
- Directorate for Biological Sciences
- Medical Research Council (MR/K024000/1, MR/M015815/1, MR/J005215/1)
- Engineering and Physical Sciences Research Council (EP/J017698/1, EP/J005193/1)
- Biotechnology and Biological Sciences Research Council (BB/M00211X/1)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, retinal degeneration, visual function, retinal sensitivity, electroretinogram, vector dose, intraocular inflammation, visual acuity, canine model, species differences, long-term efficacy and safety
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adolescent, Animals, Child, Disease Models, Animal, Dogs, Genetic Vectors, Humans, Mutation, Retina, Vision, Ocular, Genetic Therapy, DNA, Complementary, Disease Progression, cis-trans-Isomerases, Photoreceptor Cells, Vertebrate, Young Adult, Leber Congenital Amaurosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
